Fri, June 18, 2021
Thu, June 17, 2021
Wed, June 16, 2021
Tue, June 15, 2021

Joel Beatty Maintained (BPMC) at Buy with Increased Target to $123 on, Jun 17th, 2021

Joel Beatty of Baird, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Increased Target from $119 to $123 on, Jun 17th, 2021.

Joel has made no other calls on BPMC in the last 4 months.



There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 3 agree with Joel's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $101 on, Friday, April 30th, 2021
  • Brad Canino of "Credit Suisse" Initiated at Hold and Held Target at $100 on, Wednesday, March 31st, 2021
  • Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $95 on, Thursday, February 18th, 2021


This is the rating of the analyst that currently disagrees with Joel


  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Decreased Target to $110 on, Thursday, April 29th, 2021